Switch to Patients and Caregivers
Email Page
Print Page
Herceptin Access Solutions—Committed to Helping Your Patients Access Herceptin (trastuzumab)
At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe they should be accessible to the patients who need them. Herceptin Access Solutions helps resolve specific access and reimbursement issues for individual patients every day.
Coverage and Reimbursement
For you and your patients, Herceptin Access Solutions provides coverage and reimbursement support, patient assistance and informational resources. Our specialists are passionate about helping patients access Herceptin and exploring every appropriate solution to coverage or reimbursement issues.
Patient Assistance
To learn more about our patient assistance programs, please click on the button that applies to your patient.
- Your patient is uninsured or rendered uninsured by payer denial
- Your patient has health insurance and needs help with co-pay*
Informational Resources
We know it’s important to have the right information at your fingertips. With this in mind, we’ve compiled a list of informational resources you may find useful.
Herceptin (trastuzumab) Indications
Adjuvant indications: Herceptin is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature)* breast cancer:
- As part of a treatment regimen containing doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
- With docetaxel and carboplatin
- As a single agent following multi-modality anthracycline-based therapy
*ER/PR-negative, tumor size >2 cm, age <35 years, or histological and/or nuclear grade 2 or 3.
Metastatic indications: Herceptin is indicated:
- In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer
- As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Herceptin Boxed WARNINGS and Additional Important Safety Information
Herceptin administration can result in sub-clinical and clinical cardiac failure manifesting as congestive heart failure and decreased left ventricular ejection fraction. Serious infusion reactions and pulmonary toxicity have occurred; fatal infusion reactions have been reported. Exacerbation of chemotherapy-induced neutropenia has also occurred. Herceptin can cause oligohydramnios and fetal harm when administered to a pregnant woman. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.
Please see the Herceptin full prescribing information including Boxed WARNINGS and additional important safety information.
*Co-pay refers to a cost-sharing arrangement in which members of health insurance plans pay a specified charge for a product or service, such as a prescription or an office visit. Members are typically responsible for this payment at the time of service.
Privacy information: This site is being offered to you, the health care provider, on behalf of your patients, with the understanding that if you intend to request the assistance of Herceptin Access Solutions with respect to access to or reimbursement for a Genentech medicine for a specific patient, you must obtain a signed Patient Authorization and Notice of Release of Information (PAN) form (description/PDF) from your patient to provide his or her information to Herceptin Access Solutions. Any information submitted to Herceptin Access Solutions will remain confidential and will not be used for promotional purposes.
If you would like to learn more about protecting the privacy of personal health information, please go to the U.S. Department of Health & Human Services website at www.hhs.gov/ocr/hipaa/.
Herceptin Access Solutions provides forms and documents in Adobe® Portable Document Format (PDF). In order to view PDF files, you must have Adobe® Reader® installed on your computer. If you don't have Adobe Reader or have an earlier version of Adobe Acrobat, you can download the most recent version for free at the Adobe Reader download site.
To open a PDF, simply click on the link. This will open the PDF in a new window. All PDFs can be printed or saved to your computer using the tools at the top of the PDF window. The "type-in" PDFs allow you to type directly into the form fields (instead of printing and filling out by hand).
